HOME >> BIOLOGY >> NEWS
Data show investigational antibiotic safe, effective in preventing travelers diarrhea

New Orleans, LA — New data suggest the investigational drug rifaximin, a non-absorbed (less than .5%) antibiotic with few side effects and low potential for resistance, is effective in preventing travelers' diarrhea, an illness that affects up to 60 percent of international travelers. Until now, antimicrobial prophylaxis, while effective, has been discouraged because of side effects and the encouragement of resistance. The study results, presented Sunday, May 16 at the 2004 Digestive Disease Week (DDW) annual meeting by lead investigator, Herbert L. DuPont, M.D., Chief of the Internal Medicine Service at St. Luke's Episcopal Hospital in Houston, showed that, over two weeks, 85 percent of the rifaximin-treated subjects remained free of diarrhea, compared with 49 percent of the placebo-treated subjects.

Dr. DuPont is also Director, Center for Infectious Diseases, University of Texas, Houston School of Public Health and Vice-Chairman, Department of Medicine at Baylor College of Medicine.

Travelers' diarrhea threatens up to 50 million persons going to Mexico and Latin America, Africa and southern Asia each year. The illness can render travelers bed ridden for a full day or more, and considerably decrease their energy for up to a week or longer. In addition, a bout of travelers' diarrhea can also cause chronic diarrhea and long-lasting irritable bowel syndrome in some people. The antibiotic, rifaximin, with the projected brand name of Xifaxan, is currently under review by the U.S. Food and Drug Administration. It has previously been shown by researchers to be a safe and effective form of therapy for treatment of travelers' diarrhea in clinical studies conducted in Mexico, Peru, India and Kenya and has been prescribed internationally since 1987 and is currently approved in 17 countries worldwide.

"This is potentially one of the most important advances over the past 50 years toward reducing the occurrence of illness of travelers to
'"/>


16-May-2004


Page: 1 2 3

Related biology news :

1. Hemophilia therapy update: New information on investigational Factor VIII therapy development
2. New research on investigational Alzheimers disease treatment suggests significant improvement of symptoms
3. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
4. Smart antibiotics may result from UCLA research
5. K-State researcher working to improve alternatives to equine antibiotics
6. Bacterial protein recycling factor possible key to new class of antibiotics
7. Bacteria spill their guts to aid researchers in quest for new antibiotics
8. Molecule that blocks key bacterial enzyme may lead to new antibiotics
9. Does antibiotic use contribute to allergies?
10. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
11. Tigecycline - antibiotic evaluated in surveillance trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio ... findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease ... hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, ... company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, ... its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at ... requiring fast track capacity to provide patients with urgently needed vaccines and other ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... entered into a strategic partnership whereby Catalent will provide support for the development, ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... software for the life sciences industry, today announced the release of its ... specifically for Medical Science Liaisons (MSLs) and other field medical professionals. ...
Breaking Biology Technology:
Cached News: